Dataset Information

The Prevalence and Correlates of Probable Major Depressive Disorder and Probable Generalized Anxiety Disorder during the COVID-19 Pandemic. Results of a Nationally Representative Survey in Germany.

ABSTRACT: The aim was to clarify the prevalence and correlates of probable major depressive disorder and probable generalized anxiety disorder in the general adult population during the COVID-19 pandemic. Data were derived from a nationally representative survey (August and September 2021). In total, n = 3075 individuals took part. To quantify probable generalized anxiety disorder, the established Generalized Anxiety Disorder-7 (GAD-7; cutoff of 10) was used. Moreover, the Patient Health Questionnaire-9 (PHQ-9; cutoff of 10) was used to quantify probable major depressive disorder. The prevalence of probable major depressive disorder was 20.0% and the prevalence of probable generalized anxiety disorder was 13.4%. Particularly high prevalence rates were observed for younger individuals, individuals with migration background and individuals with at least one chronic disease. The likelihood of probable major depressive disorder was positively associated with younger age, being unmarried, having a migration background, smoking, daily alcohol intake, the presence of chronic diseases and lower self-rated health. Similarly, the likelihood of probable generalized anxiety disorder was positively associated with younger age, being unmarried, smoking, the presence of chronic diseases and lower self-rated health. In conclusion, the magnitude of probable major depressive disorder and probable generalized anxiety disorder in Germany in late summer of 2021 was highlighted. Identifying the correlates of them may help to tackle individuals at higher risk.

SUBMITTER: Hajek A

PROVIDER: S-EPMC8656556 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundRecent studies have investigated the potential of treatments that modify the gut microbiome, such as fecal microbiota transplantation and probiotics, in individuals with psychiatric illnesses.ObjectiveThe aim of this study was to investigate the safety, tolerability, and efficacy of a novel gut microbiome therapeutic, Microbial Ecosystem Therapuetic-2 (MET-2), in people with depression and anxiety.MethodsIn this phase 1, open-label trial, 12 adults diagnosed with major depressive disorder, generalized anxiety disorder, or both were recruited. Over 8 weeks, participants consumed three capsules per day, orally, of an encapsulated microbial therapeutic (MET-2), which contained 40 strains of bacteria that were purified and lab-grown from the stool of a single healthy donor. Participants were assessed biweekly using clinical scales and questionnaires in order to evaluate the safety, efficacy, and tolerability of the therapeutic.ResultsThe therapeutic was found to be generally safe and tolerable, with limited adverse events and side effects and no serious adverse events. Of the 12 individuals included in this study, 9 (75%) responded to treatment (50% improvement in Montgomery-Asberg Depression Rating Scale [MADRS] scores, 7-item Generalized Anxiety Disorder scale [GAD-7] scores, or both, from baseline to the week-8 visit). Over the course of 10 weeks, MET-2 significantly decreased mean MADRS and GAD-7 scores (MADRS: F2.731, 30.05=8.784, P<.001; GAD-7: F2.778, 30.55= 9.638, P<.001). Multiple comparisons with Bonferroni adjustments showed a significant reduction in MADRS scores from baseline (mean 19.00, SD 4.843) to week 6 (mean 11.25, SD 8.001; P=.009), week 8 (mean 8.667, SD 8.732; P=.002), and week 10 (mean 8.250, SD 9.304; P=.006). Multiple comparisons showed a significant reduction in GAD-7 scores from baseline (mean 13.58, SD 4.010) to week 4 (mean 9.167, SD 5.096; P=.03), week 6 (mean 7.667, SD 4.539; P=.004), week 8 (mean 7.333, SD 6.583; P=.03), and week 10 (mean 7.500, SD 6.448; P=.03).ConclusionsThe findings from this study are the first to provide evidence for the role of microbial ecosystem therapy in treating depression and anxiety. However, a double-blind, randomized controlled trial with a larger sample size is needed for more conclusive results.Trial registrationClinicalTrials.gov NCT04052451; https://www.clinicaltrials.gov/ct2/show/NCT04052451.International registered report identifier (irrid)RR2-10.2196/17223.

Dataset Information

The Prevalence and Correlates of Probable Major Depressive Disorder and Probable Generalized Anxiety Disorder during the COVID-19 Pandemic. Results of a Nationally Representative Survey in Germany.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets